drugset / Trial / NCT05965284

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

NCT05965284

Phase 4 Recruiting 40 enrolled Chinese SLE Treatment And Research Group
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with Telitacicept combined with azathioprine and azathioprine alone in remission-maintenance treatment of AAV.

Timeline

Start
2023-03-09
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Telitacicept Protein / enzyme biologic 160 mg Subcutaneous
Background Azathioprine Small molecule 100 mg